1 results match your criteria: "3 Medical Department - Centre for Oncology and Haematology[Affiliation]"
Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.
Radiol Oncol
June 2014
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3 Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria ; Applied Cancer Research - Institution for Translational Research Vienna (ACR -ITR VIEnna), Vienna, Austria.
Background: The attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a single target structure alone. Vascular endothelial growth factor (VEGF) over-expression is frequently observed in human epidermal growth factor receptor 2 (Her2/neu) positive patients with breast cancer and over-expression of the proto-oncogene Her2/neu is associated with an up-regulation of VEGF.
Case Report: The case of a Her2/neu positive patient with breast cancer who refused cytotoxic chemotherapy with its potential side effects as well as mastectomy is presented.